fda indications for semaglutide approves first-ever oral GLP-1RA obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults TrimRX | Wegovy vs Ozempic:

The sustained visual gains demonstrated over three years are truly remarkable for this population, said Allen Ho, MD, Director of Retina Research at Wills Eye Hospital and Chief Medical Advisor for Nanoscope

Multiple studies have shown reductions in inflammatory markers among people taking GLP-1 agonists, and patients frequently report improvements in inflammation-related conditions

aOR, adjusted odds ratio

Female sex and age : Women, especially those over 40, have a higher incidence of gallstones

Semaglutide has already been in use for several years under the brand name Ozempic for the treatment of type 2 diabetes

Semaglutide GLP-1, initially developed for managing type 2 diabetes, has been FDA-approved since June 2021 for chronic weight management in adults with obesity or those who are overweight and have at least one weight-related condition such as hypertension, type 2 diabetes, or hyperlipidemia